EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Progestogen supplementation to prevent miscarriage: Evidence and controversies

Gabriele Saccone iD, Vincenzo Berghella, Moti Gulersen, Attilio Di Spiezio Sardo

International Journal of Gynecology & Obstetrics · 2026

DOI: 10.1002/ijgo.70793 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Gynecology & Obstetrics, 2026. Verfasst von Gabriele Saccone und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Progestins, Progesterone, Abortion, Spontaneous. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Progesterone plays a key role in the establishment and maintenance of pregnancy and its deficiency has been associated with early pregnancy loss. Progestogen supplementation has therefore been widely investigated as a preventive strategy against miscarriage, particularly in women with recurrent pregnancy loss or threatened miscarriage or after assisted reproductive technologies. However, the overall evidence remains inconclusive. Meta‐analyses of randomized trials, including the large PROMISE and PRISM studies, have not demonstrated a significant overall benefit in live birth rates, although a possible advantage was observed in women with both early bleeding and prior miscarriages. The biological plausibility of supplementation lies in the luteal–placental shift, when the placenta assumes progesterone production after the first trimester. Yet, low progesterone levels in early pregnancy might often represent a marker of a non‐viable gestation rather than the underlying cause of miscarriage. The optimal route and duration of treatment remain uncertain. Vaginal and subcutaneous progesterone offer comparable efficacy to intramuscular formulations, with better tolerability and compliance. Current evidence does not support universal progesterone supplementation in early pregnancy, but individualized treatment might be considered for women at increased risk, based on clinical history. Future research should focus on identifying reliable markers of luteal deficiency, refining patient selection and comparing different administration routes and serum thresholds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProgestinsProgesteroneAbortion, SpontaneousHumansFemalePregnancyAbortion, HabitualRandomized Controlled Trials as TopicAdministration, Intravaginal

Stichwörter der Autor:innen

abortionmiscarriageprogesterone

Substanzen

ProgestinsProgesterone

Autor:innen und Institutionen

  • Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.
  • Division of Maternal Fetal Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Department of Public Health, School of Medicine, University of Naples Federico II, Naples, Italy.

ORCID-Profile: Gabriele Saccone

Zitieren

APA

Saccone, G., Berghella, V., Gulersen, M., & Di Spiezio Sardo, A. (2026). Progestogen supplementation to prevent miscarriage: Evidence and controversies. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.70793

Vancouver

Saccone G, Berghella V, Gulersen M, Di Spiezio Sardo A. Progestogen supplementation to prevent miscarriage: Evidence and controversies. International Journal of Gynecology & Obstetrics. 2026. doi:10.1002/ijgo.70793

BibTeX
@article{Saccone2026,
  author = {Saccone, Gabriele and Berghella, Vincenzo and Gulersen, Moti and Di Spiezio Sardo, Attilio},
  title = {Progestogen supplementation to prevent miscarriage: Evidence and controversies},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2026},
  doi = {10.1002/ijgo.70793}
}
Kostenlos starten →